Mouse anti-mouse mAbs

Benefits of mouse anti-mouse mAbs
Benefits of mouse anti-mouse mAbs

Recombinant monoclonal antibodies for in vivo use

InvivoGen offers an expanding collection of InvivoFit recombinant mouse anti-mouse monoclonal antibodies (mAbs). These mAbs were engineered to limit their immunogenicity for a constant efficacy upon repeated injections in mice. Our collection includes mAbs targeting immune checkpoints such as PD-1, and tumor-associated antigens such as gp75. These mAbs are produced in Chinese hamster ovary (CHO) cells and are provided in an  InvivoFit grade, a high-quality standard specifically adapted to in vivo studies.


Features of InvivoFit™ mouse anti-mouse mAbs:

  • Sequence is 85% to 100% murine
  • Guaranteed sterile, endotoxin level: <1 EU/mg
  • Suitable for parenteral delivery in mice (azide-free) 
  • Low aggregation: < 5%
  • Produced in both animal-free facilities and defined media


InvivoGen's recombinant mouse anti-mouse mAbs include antibodies for which the sequence is either 100% mouse origin (constant and variable regions), or ~85% mouse origin (constant regions) and ~15% non-mouse origin (variable regions). The minimal use of xenogeneic sequences limits the immunogenicity of the mAb [1]. Indeed, a major pitfall encountered in murine in vivo studies aimed at evaluating the activity of a mAb upon repeated injections is the decrease and loss of antibody performance if its sequence is not of mouse origin. Repeated injections in mice lead to anti-species antibody generation by the host (e.g. anti-rat antibodies if the mAb was produced in rats). This occurrence increases as the fraction of non-mouse sequences increases. Replacing xenogeneic sequences with mouse sequences reduces antibodies immunogenicity, and thus helps retain their activity in vivo.

InvivoGen provides murine IgG1e3 and murine IgG2a isotype control mAbs for use with the mouse anti-mouse mAbs. These antibodies comprise the variable region of a mouse monoclonal antibody targeting E. coli β-galactosidase and the constant region of corresponding isotypes.



1. Brüggemann M. et al., 1989. The immunogenicity of chimeric antibodies. J. Exp. Med. 170:2153-2157. 



Customer Service
& Technical Support
Contact us
Shopping cart is empty